{"id":11352,"date":"2026-08-24T17:34:29","date_gmt":"2026-08-24T15:34:29","guid":{"rendered":"https:\/\/ab-science.excalibra.com\/?page_id=11352"},"modified":"2026-09-29T11:14:31","modified_gmt":"2026-09-29T09:14:31","slug":"ab8939","status":"publish","type":"page","link":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/","title":{"rendered":"AB8939"},"content":{"rendered":"<div class=\"wpb-content-wrapper\" id=\"wpb-content-root\"><p>[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-hero\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n<style>\n.ab8939-page{font-family:inherit;color:#1d2a40}.ab8939-shell{max-width:1180px;margin:0 auto;padding:88px 32px}.ab8939-hero{background:linear-gradient(135deg,#fff 0%,#eef4fb 100%)}.ab8939-kicker{display:flex;align-items:center;gap:16px;margin:0 0 34px;color:#5e87c5;font-size:13px;font-weight:700;letter-spacing:2.3px;text-transform:uppercase}.ab8939-kicker:before{content:\"\";width:54px;height:2px;background:#f15a24;flex:0 0 54px}.ab8939-title{margin:0;color:#1d2a40;font-family:Arial,Helvetica,sans-serif;font-size:clamp(72px,10vw,150px);font-weight:400;line-height:.86;letter-spacing:-.035em;font-variant-numeric:lining-nums;font-feature-settings:\"lnum\" 1}.ab8939-dot{color:#5e87c5}.ab8939-subtitle{margin:42px 0 18px;color:#315f9f;font-size:18px;font-weight:700;letter-spacing:2px;text-transform:uppercase}.ab8939-lead{max-width:850px;margin:0;color:#617896;font-size:clamp(22px,2.2vw,34px);line-height:1.35}.ab8939-section{background:#fff}.ab8939-section-alt{background:#eaf2fb}.ab8939-section-blue{background:#3868a4;color:#fff}.ab8939-section h2{max-width:950px;margin:0 0 38px;font-size:clamp(42px,5.2vw,76px);font-weight:300;line-height:1.04;letter-spacing:-.03em}.ab8939-section p{font-size:18px;line-height:1.65;color:#617896}.ab8939-section-blue p{color:rgba(255,255,255,.82)}.ab8939-intro{max-width:980px}.ab8939-intro p+p{margin-top:22px}.ab8939-facts{margin-top:52px}.ab8939-fact>.vc_column-inner{height:100%;padding:32px!important;border-radius:28px;background:#eaf2fb;border-top:7px solid #5e87c5}.ab8939-fact strong{display:block;margin-bottom:10px;color:#315f9f;font-size:13px;letter-spacing:1.6px;text-transform:uppercase}.ab8939-fact span{display:block;color:#1d2a40;font-size:29px;font-weight:500;line-height:1.15}.ab8939-diagram img{width:100%;border-radius:30px;box-shadow:0 22px 55px rgba(19,39,70,.18)}.ab8939-card>.vc_column-inner{height:100%;padding:38px!important;border-radius:30px;background:#fff}.ab8939-card h3{margin:0 0 18px;color:#315f9f;font-size:28px;line-height:1.15}.ab8939-card p{margin:0;color:#617896;font-size:17px;line-height:1.65}.ab8939-cta{background:#1d2a40;color:#fff}.ab8939-cta .ab8939-shell{display:flex;align-items:center;justify-content:space-between;gap:36px}.ab8939-cta h2{margin:0;color:#fff;font-size:clamp(34px,4vw,58px);font-weight:300;line-height:1.08}.ab8939-button{display:inline-flex;align-items:center;justify-content:center;padding:15px 24px;border-radius:999px;background:#f15a24;color:#fff!important;font-weight:700;text-decoration:none!important;white-space:nowrap}.ab8939-fact>.vc_column-inner,.ab8939-card>.vc_column-inner{transition:transform .25s ease,box-shadow .25s ease}@media(hover:hover) and (pointer:fine){.ab8939-fact>.vc_column-inner:hover,.ab8939-card>.vc_column-inner:hover{transform:translateY(-5px);box-shadow:0 18px 38px rgba(20,45,80,.15)}}@media(max-width:767px){.ab8939-shell{padding:58px 22px}.ab8939-kicker{font-size:10px;letter-spacing:1.5px}.ab8939-kicker:before{width:34px;flex-basis:34px}.ab8939-title{font-size:clamp(66px,25vw,100px)}.ab8939-subtitle{font-size:15px}.ab8939-lead{font-size:22px}.ab8939-section h2{font-size:42px}.ab8939-section p{font-size:16px}.ab8939-fact,.ab8939-card{margin-bottom:18px}.ab8939-cta .ab8939-shell{display:block}.ab8939-button{margin-top:28px}}@media(prefers-reduced-motion:reduce){.ab8939-fact>.vc_column-inner,.ab8939-card>.vc_column-inner{transition:none!important;transform:none!important}}\n<\/style>\n<div class=\"ab8939-shell\">\n<p class=\"ab8939-kicker\">M\u00e9dicament en d\u00e9veloppement<\/p>\n<h1 class=\"ab8939-title\">AB8939<\/h1>\n<p class=\"ab8939-subtitle\">Leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA)<\/p>\n<p class=\"ab8939-lead\">Une mol\u00e9cule synth\u00e9tique con\u00e7ue pour s\u2019attaquer directement aux cellules canc\u00e9reuses.<\/p>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<br \/>\n[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-section\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n<div class=\"ab8939-shell\">\n<p class=\"ab8939-kicker\">Pr\u00e9sentation g\u00e9n\u00e9rale<\/p>\n<h2>Une seconde mol\u00e9cule au parcours distinct<\/h2>\n<div class=\"ab8939-intro\">\n<p>AB8939 est la seconde mol\u00e9cule d\u00e9velopp\u00e9e par AB Science, aux c\u00f4t\u00e9s du masitinib. Les deux suivent des chemins tr\u00e8s diff\u00e9rents. Le masitinib agit sur des cellules du syst\u00e8me immunitaire ; AB8939 s\u2019attaque directement aux cellules canc\u00e9reuses.<\/p>\n<p>Il s\u2019agit d\u2019une mol\u00e9cule enti\u00e8rement synth\u00e9tique, con\u00e7ue et brevet\u00e9e par AB Science, qui en d\u00e9tient l\u2019int\u00e9gralit\u00e9 des droits. Elle est d\u00e9velopp\u00e9e en priorit\u00e9 dans la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb, un cancer du sang dans lequel des cellules anormales se multiplient rapidement dans la moelle osseuse, envahissent le sang et emp\u00eachent la fabrication normale des cellules sanguines. Les patients qui ne peuvent pas recevoir de chimioth\u00e9rapie intensive disposent aujourd\u2019hui de peu d\u2019options efficaces.<\/p>\n<p>AB8939 a \u00e9t\u00e9 retenue pour cette maladie parce que les cellules leuc\u00e9miques s\u2019y divisent tr\u00e8s vite, ce qui les rend particuli\u00e8rement sensibles \u00e0 son mode d\u2019action. La mol\u00e9cule est actuellement \u00e9valu\u00e9e dans une \u00e9tude de phase 1\/2, seule ou en association avec un traitement existant. Il s\u2019agit de l\u2019\u00e9tude <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05211570\" target=\"_blank\" rel=\"noopener noreferrer\">AB18001 (NCT05211570)<\/a>.<\/p>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<br \/>\n[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-section ab8939-section-blue\u00a0\u00bb][vc_column][vc_column_text]<\/p>\n<div class=\"ab8939-shell\">\n<p class=\"ab8939-kicker\" style=\"color:rgba(255,255,255,.78)\">M\u00e9canisme d\u2019action<\/p>\n<h2>Agir sur deux m\u00e9canismes cl\u00e9s de la maladie<\/h2>\n<div class=\"ab8939-intro\">\n<p>Deux obstacles expliquent pourquoi la leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb revient si souvent apr\u00e8s un traitement. Le premier est la r\u00e9sistance : les cellules canc\u00e9reuses parviennent \u00e0 neutraliser les m\u00e9dicaments, notamment en les rejetant hors de la cellule avant qu\u2019ils n\u2019agissent. Le second est la persistance de cellules souches leuc\u00e9miques, des cellules dormantes que les traitements atteignent mal et qui suffisent \u00e0 relancer la maladie. AB8939 a \u00e9t\u00e9 con\u00e7ue pour r\u00e9pondre \u00e0 ces deux probl\u00e8mes \u00e0 la fois.<\/p>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][vc_column_text el_class=\u00a0\u00bbab8939-shell ab8939-diagram\u00a0\u00bb]<\/p>\n<div class=\"ab8939-process\" role=\"list\" aria-label=\"Action p\u00e9dagogique d\u2019AB8939 sur l\u2019\u00e9chafaudage cellulaire\">\n<article class=\"ab8939-process__step\" role=\"listitem\"><span class=\"ab8939-process__number\">1<\/span><\/p>\n<div class=\"ab8939-process__visual ab8939-process__visual--microtubules\" aria-hidden=\"true\"><i><\/i><i><\/i><i><\/i><\/div>\n<h3>Microtubules<\/h3>\n<p>L\u2019\u00e9chafaudage interne organise la division de la cellule leuc\u00e9mique.<\/p>\n<\/article>\n<article class=\"ab8939-process__step\" role=\"listitem\"><span class=\"ab8939-process__number\">2<\/span><\/p>\n<div class=\"ab8939-process__visual ab8939-process__visual--molecule\" aria-hidden=\"true\"><b>AB8939<\/b><\/div>\n<h3>Action d\u2019AB8939<\/h3>\n<p>La mol\u00e9cule cible et d\u00e9stabilise les microtubules n\u00e9cessaires \u00e0 la division.<\/p>\n<\/article>\n<article class=\"ab8939-process__step\" role=\"listitem\"><span class=\"ab8939-process__number\">3<\/span><\/p>\n<div class=\"ab8939-process__visual ab8939-process__visual--rupture\" aria-hidden=\"true\"><i><\/i><i><\/i><i><\/i><\/div>\n<h3>Rupture de l\u2019\u00e9chafaudage<\/h3>\n<p>La structure se d\u00e9sorganise et la s\u00e9paration cellulaire ne peut plus aboutir.<\/p>\n<\/article>\n<article class=\"ab8939-process__step\" role=\"listitem\"><span class=\"ab8939-process__number\">4<\/span><\/p>\n<div class=\"ab8939-process__visual ab8939-process__visual--collapse\" aria-hidden=\"true\"><i><\/i><\/div>\n<h3>Effondrement de la cellule<\/h3>\n<p>La division est bloqu\u00e9e et la cellule leuc\u00e9mique s\u2019effondre.<\/p>\n<\/article>\n<\/div>\n<p>[\/vc_column_text][vc_row_inner gap=\u00a0\u00bb20&Prime; equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbab8939-shell ab8939-mechanism-grid\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-card ab8939-mechanism-card ab8939-mechanism-card&#8211;resistance\u00a0\u00bb][vc_column_text]<\/p>\n<p class=\"ab8939-mechanism-label\">M\u00e9canisme 1<\/p>\n<h3>R\u00e9sistance<\/h3>\n<p>AB8939 n\u2019est pas expuls\u00e9e par la pompe d\u2019efflux et n\u2019est pas d\u00e9grad\u00e9e par la my\u00e9loperoxydase. Elle contourne ainsi deux m\u00e9canismes fr\u00e9quents de neutralisation des m\u00e9dicaments.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-card ab8939-mechanism-card ab8939-mechanism-card&#8211;persistence\u00a0\u00bb][vc_column_text]<\/p>\n<p class=\"ab8939-mechanism-label\">M\u00e9canisme 2<\/p>\n<h3>Persistance<\/h3>\n<p>AB8939 bloque les enzymes ALDH1A1 et ALDH2 dont d\u00e9pendent les cellules souches leuc\u00e9miques. Elle pourrait ainsi atteindre le r\u00e9servoir de cellules capables de survivre au traitement et de relancer la maladie.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<br \/>\n[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-metrics-section\u00a0\u00bb][vc_column][vc_row_inner gap=\u00a0\u00bb20&Prime; equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbab8939-shell ab8939-facts ab8939-facts&#8211;programme ab8939-facts&#8211;primary\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-fact\u00a0\u00bb][vc_column_text]<strong>Phase de d\u00e9veloppement<\/strong><span>Phase 1\/2<\/span>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-fact\u00a0\u00bb][vc_column_text]<strong>Dur\u00e9e du protocole<\/strong><span>14\/28 jours<\/span>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner gap=\u00a0\u00bb20&Prime; equal_height=\u00a0\u00bbyes\u00a0\u00bb el_class=\u00a0\u00bbab8939-shell ab8939-facts ab8939-facts&#8211;programme ab8939-facts&#8211;secondary\u00a0\u00bb][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-fact ab8939-fact&#8211;orange\u00a0\u00bb][vc_column_text]<strong>Population concern\u00e9e<\/strong><span>\u2248 80\u00a0000 patients \u2014 Europe et \u00c9tats-Unis<\/span><small>(patients ne recevant pas de greffe de cellules souches et en rechute apr\u00e8s une premi\u00e8re ligne)<\/small>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/2&Prime; el_class=\u00a0\u00bbab8939-fact ab8939-fact&#8211;orange\u00a0\u00bb][vc_column_text]<strong>Taille de march\u00e9<\/strong><span>600 millions d\u2019euros \u2014 Europe + \u00c9tats-Unis<\/span>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-hero\u00a0\u00bb][vc_column][vc_column_text] M\u00e9dicament en d\u00e9veloppement AB8939 Leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) Une mol\u00e9cule synth\u00e9tique con\u00e7ue pour s\u2019attaquer directement aux cellules canc\u00e9reuses. [\/vc_column_text][\/vc_column][\/vc_row] [vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-section\u00a0\u00bb][vc_column][vc_column_text] Pr\u00e9sentation g\u00e9n\u00e9rale Une seconde mol\u00e9cule au parcours distinct AB8939 est la seconde mol\u00e9cule d\u00e9velopp\u00e9e par AB Science, aux c\u00f4t\u00e9s du masitinib. Les deux suivent des chemins tr\u00e8s diff\u00e9rents.&hellip;<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":11294,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-11352","page","type-page","status-publish","hentry","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.2 (Yoast SEO v28.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB8939 &#8211; AB Science<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB8939\" \/>\n<meta property=\"og:description\" content=\"[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-hero\u00a0\u00bb][vc_column][vc_column_text] M\u00e9dicament en d\u00e9veloppement AB8939 Leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) Une mol\u00e9cule synth\u00e9tique con\u00e7ue pour s\u2019attaquer directement aux cellules canc\u00e9reuses. [\/vc_column_text][\/vc_column][\/vc_row] [vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-section\u00a0\u00bb][vc_column][vc_column_text] Pr\u00e9sentation g\u00e9n\u00e9rale Une seconde mol\u00e9cule au parcours distinct AB8939 est la seconde mol\u00e9cule d\u00e9velopp\u00e9e par AB Science, aux c\u00f4t\u00e9s du masitinib. Les deux suivent des chemins tr\u00e8s diff\u00e9rents.&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-29T09:14:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/ab8939\\\/\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/ab8939\\\/\",\"name\":\"AB8939 &#8211; AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-08-24T15:34:29+00:00\",\"dateModified\":\"2026-09-29T09:14:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/ab8939\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/ab8939\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/ab8939\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Public\",\"item\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/public\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"AB8939\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/ab-science.excalibra.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB8939 &#8211; AB Science","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"AB8939","og_description":"[vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-hero\u00a0\u00bb][vc_column][vc_column_text] M\u00e9dicament en d\u00e9veloppement AB8939 Leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) Une mol\u00e9cule synth\u00e9tique con\u00e7ue pour s\u2019attaquer directement aux cellules canc\u00e9reuses. [\/vc_column_text][\/vc_column][\/vc_row] [vc_row full_width=\u00a0\u00bbstretch_row_content_no_spaces\u00a0\u00bb el_class=\u00a0\u00bbab8939-page ab8939-section\u00a0\u00bb][vc_column][vc_column_text] Pr\u00e9sentation g\u00e9n\u00e9rale Une seconde mol\u00e9cule au parcours distinct AB8939 est la seconde mol\u00e9cule d\u00e9velopp\u00e9e par AB Science, aux c\u00f4t\u00e9s du masitinib. Les deux suivent des chemins tr\u00e8s diff\u00e9rents.&hellip;","og_url":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/","og_site_name":"AB Science","article_modified_time":"2026-09-29T09:14:31+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/","url":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/","name":"AB8939 &#8211; AB Science","isPartOf":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#website"},"datePublished":"2026-08-24T15:34:29+00:00","dateModified":"2026-09-29T09:14:31+00:00","breadcrumb":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ab-science.excalibra.com\/fr\/public\/ab8939\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ab-science.excalibra.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Public","item":"https:\/\/ab-science.excalibra.com\/fr\/public\/"},{"@type":"ListItem","position":3,"name":"AB8939"}]},{"@type":"WebSite","@id":"https:\/\/ab-science.excalibra.com\/fr\/#website","url":"https:\/\/ab-science.excalibra.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ab-science.excalibra.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ab-science.excalibra.com\/fr\/#organization","name":"AB Science","url":"https:\/\/ab-science.excalibra.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/ab-science.excalibra.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/comments?post=11352"}],"version-history":[{"count":11,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11352\/revisions"}],"predecessor-version":[{"id":11860,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11352\/revisions\/11860"}],"up":[{"embeddable":true,"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/pages\/11294"}],"wp:attachment":[{"href":"https:\/\/ab-science.excalibra.com\/fr\/wp-json\/wp\/v2\/media?parent=11352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}